FDA wins major victory in campaign against stem cell clinics that marketing bogus and potentially hazardous products
One bioethical issue our Observatory is following is the proliferation of clinics offering stem cell treatments, many of which do not meet the necessary quality requirements. We published our first article on this problem in 2017 (see HERE and also North America’s two cell therapy companies fined for medical fraud. Is it the tip of an iceberg?). We congratulate the FDA on their campaign to protect patients and the advance of clinical applications of these promising techniques. In this regard, we cite a CNN News article published on June 4, 2019.
(CNN) The US Food and Drug Administration won a major legal victory in its ongoing effort to crack down on clinics marketing bogus and potentially hazardous stem cell products.
On Monday, a federal judge in Miami granted the FDA an injunction to prevent the Florida-based US Stem Cell Clinic from offering treatments designed to create stem cells from body fat and administering them intravenously or directly into the spinal cords of patients to treat Parkinson’s disease, amyotrophic lateral sclerosis, chronic obstructive pulmonary disease and other serious conditions.